Margaret M. Doherty

2.1k total citations
28 papers, 1.5k citations indexed

About

Margaret M. Doherty is a scholar working on Surgery, Pharmacology and Oncology. According to data from OpenAlex, Margaret M. Doherty has authored 28 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 9 papers in Pharmacology and 7 papers in Oncology. Recurrent topics in Margaret M. Doherty's work include Pharmacogenetics and Drug Metabolism (9 papers), Liver Disease Diagnosis and Treatment (7 papers) and Liver Disease and Transplantation (7 papers). Margaret M. Doherty is often cited by papers focused on Pharmacogenetics and Drug Metabolism (9 papers), Liver Disease Diagnosis and Treatment (7 papers) and Liver Disease and Transplantation (7 papers). Margaret M. Doherty collaborates with scholars based in Australia, United States and Canada. Margaret M. Doherty's co-authors include Roy L. Gordon, Jeanne M. LaBerge, Ernest J. Ring, William N. Charman, Nancy L. Ascher, John P. Roberts, John R. Lake, K. Sandy Pang, Kenneth A. Somberg and Ziv J. Haskal and has published in prestigious journals such as Journal of Clinical Oncology, Radiology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Margaret M. Doherty

28 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Margaret M. Doherty Australia 19 710 562 510 355 256 28 1.5k
R. Raedsch Germany 25 771 1.1× 711 1.3× 691 1.4× 718 2.0× 242 0.9× 77 1.9k
A. Stiehl Germany 28 1.1k 1.5× 937 1.7× 809 1.6× 782 2.2× 414 1.6× 103 2.2k
Gabriele Kirchner Germany 25 681 1.0× 323 0.6× 339 0.7× 366 1.0× 136 0.5× 54 2.0k
W.G.M. Hardison United States 24 471 0.7× 301 0.5× 421 0.8× 570 1.6× 107 0.4× 54 1.5k
Kazumi Yamasaki Japan 16 284 0.4× 573 1.0× 602 1.2× 346 1.0× 98 0.4× 67 1.4k
P.Robert C. Harvey Canada 24 2.0k 2.9× 1.4k 2.5× 566 1.1× 415 1.2× 285 1.1× 43 2.7k
G. M. Murphy United Kingdom 26 638 0.9× 159 0.3× 341 0.7× 598 1.7× 465 1.8× 65 1.8k
S Bondesen Denmark 25 641 0.9× 199 0.4× 529 1.0× 243 0.7× 48 0.2× 50 1.8k
P Bories France 13 310 0.4× 273 0.5× 512 1.0× 244 0.7× 67 0.3× 36 1.2k
Full‐Young Chang Taiwan 21 358 0.5× 468 0.8× 499 1.0× 410 1.2× 124 0.5× 50 1.6k

Countries citing papers authored by Margaret M. Doherty

Since Specialization
Citations

This map shows the geographic impact of Margaret M. Doherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret M. Doherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret M. Doherty more than expected).

Fields of papers citing papers by Margaret M. Doherty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret M. Doherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret M. Doherty. The network helps show where Margaret M. Doherty may publish in the future.

Co-authorship network of co-authors of Margaret M. Doherty

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret M. Doherty. A scholar is included among the top collaborators of Margaret M. Doherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret M. Doherty. Margaret M. Doherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Michael, Michael & Margaret M. Doherty. (2007). Drug metabolism by tumours: its nature, relevance and therapeutic implications. Expert Opinion on Drug Metabolism & Toxicology. 3(6). 783–803. 19 indexed citations
2.
Doherty, Margaret M., et al.. (2006). Transport Is Not Rate-Limiting in Morphine Glucuronidation in the Single-Pass Perfused Rat Liver Preparation. Journal of Pharmacology and Experimental Therapeutics. 317(2). 890–900. 18 indexed citations
3.
Ellis, Andrew G., Margaret M. Doherty, Francesca Walker, et al.. (2006). Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochemical Pharmacology. 71(10). 1422–1434. 70 indexed citations
4.
Doherty, Margaret M., et al.. (2004). Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy. Journal of Clinical Oncology. 23(1). 205–229. 138 indexed citations
5.
Doherty, Margaret M., et al.. (2003). Tumoral Drug Metabolism: Perspectives and Therapeutic Implications. Current Drug Metabolism. 4(2). 131–149. 13 indexed citations
6.
Doherty, Margaret M. & William N. Charman. (2002). The Mucosa of the Small Intestine. Clinical Pharmacokinetics. 41(4). 235–253. 183 indexed citations
7.
Doherty, Margaret M. & K. Sandy Pang. (2000). Route-Dependent Metabolism of Morphine in the Vascularly Perfused Rat Small Intestine Preparation. Pharmaceutical Research. 17(3). 291–298. 39 indexed citations
8.
Doherty, Margaret M. & K. Sandy Pang. (1997). First-Pass Effect: Significance of the Intestine for Absorption and Metabolism. Drug and Chemical Toxicology. 20(4). 329–344. 52 indexed citations
9.
10.
Gordon, Roy L., Jeanne M. LaBerge, Ernest J. Ring, & Margaret M. Doherty. (1993). Recanalization of Occluded Intrahepatic Portosystemic Shunts: Use of the Colapinto Needle. Journal of Vascular and Interventional Radiology. 4(3). 441–443. 16 indexed citations
11.
Ring, Ernest J., et al.. (1993). Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion.. Radiology. 186(2). 523–527. 110 indexed citations
12.
Doherty, Margaret M. & Danna K. Carver. (1993). Transjugular Intrahepatic Portosystemic Shunt New Relief for Esophageal Varices. AJN American Journal of Nursing. 93(4). 58–63. 1 indexed citations
13.
Haskal, Ziv J., et al.. (1992). Role of parallel transjugular intrahepatic portosystemic shunts in patients with persistent portal hypertension.. Radiology. 185(3). 813–817. 43 indexed citations
14.
LaBerge, Jeanne M., Ernest J. Ring, John R. Lake, et al.. (1992). Transjugular intrahepatic portosystemic shunts: Preliminary results in 25 patients. Journal of Vascular Surgery. 16(2). 258–267. 36 indexed citations
15.
LaBerge, Jeanne M., Ernest J. Ring, John R. Lake, et al.. (1992). Transjugular intrahepatic portosystemic shunts: Preliminary results in 25 patients. Journal of Vascular Surgery. 16(2). 258–267. 34 indexed citations
16.
Gordon, Roy L., Ernest J. Ring, Jeanne M. LaBerge, & Margaret M. Doherty. (1992). Malignant biliary obstruction: treatment with expandable metallic stents--follow-up of 50 consecutive patients.. Radiology. 182(3). 697–701. 97 indexed citations
17.
Gordon, Roy L., et al.. (1990). Percutaneous Transhepatic Placement of Biliary Endoprostheses: Results in 100 Consecutive Patients. Journal of Vascular and Interventional Radiology. 1(1). 97–100. 26 indexed citations
18.
LaBerge, Jeanne M., Margaret M. Doherty, Roy L. Gordon, & Ernest J. Ring. (1990). Hilar malignancy: treatment with an expandable metallic transhepatic biliary stent.. Radiology. 177(3). 793–797. 67 indexed citations
19.
Karim, Aziz, et al.. (1977). Spironolactone: Diversity in Metabolic Pathways. Xenobiotica. 7(10). 585–600. 20 indexed citations
20.
Karim, Aziz, et al.. (1976). Species differences in the metabolism and disposition of spironolactone.. Drug Metabolism and Disposition. 4(6). 547–555. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Raedsch Breakdown of academic impact, for papers by A. Stiehl Breakdown of academic impact, for papers by Gabriele Kirchner Breakdown of academic impact, for papers by W.G.M. Hardison Breakdown of academic impact, for papers by Kazumi Yamasaki Breakdown of academic impact, for papers by P.Robert C. Harvey Breakdown of academic impact, for papers by G. M. Murphy Breakdown of academic impact, for papers by S Bondesen Breakdown of academic impact, for papers by P Bories Breakdown of academic impact, for papers by Full‐Young Chang
Rankless by CCL
2026